Live Evaluations

Taking a Deep Dive Into the Role of IL-17 Inhibitors for Psoriasis: What do PAs and NPs Need to Know? FCPANP23 Seminar-in-Depth

About

Seminar-in-Depth: Taking a Deep Dive Into the Role of IL-17 Inhibitors for Psoriasis: What do PAs and NPs Need to Know?


This activity is supported by an educational grant from UCB.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify the role of IL-17A and IL-17F inhibitors across multiple disease pathways and how therapies target this pathway

  • Discuss the benefit-risk profiles of IL-17 inhibitors for the management of psoriasis

  • Describe strategies on how to work as a multidisciplinary team to individualize patient care with IL-17 inhibitors

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

David
David Pariser, MD

Professor of Dermatology
Eastern Virginia Medical School
Norfolk, VA

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

April W. Armstrong, MD, MPH

Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen 

Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel 

David M. Pariser, MD

Dr. Pariser has disclosed that he has no relevant financial relationships with any Ineligible company in the past 24 months.

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved